If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSALV.L Regulatory News (SALV)

  • There is currently no data for SALV

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Corporate Update

29 Nov 2011 07:00

RNS Number : 9468S
3Legs Resources plc
29 November 2011
 



29 November 2011

 

3Legs Resources plc

 

 

Corporate update

 

3Legs Resources plc (the "Company"), a company focussed on the exploration and development of unconventional oil and gas resources with a particular focus on shale gas in Europe,announces the following corporate update.

 

Key points

 

Senior management appointment

 

·; Frances Morris-Jones has been engaged as Business Development Director with immediate effect

·; Previously Global Business Development Manager, Unconventional Resources at ConocoPhillips, where she was responsible for negotiating, closing and implementing the farm-in into 3Legs Resources' Baltic Basin concessions in 2009; and prior to that Vice-President, Renewal - Unconventional Gas at BP

 

Southern Poland concessions

 

·; Licence changes now agreed with the Polish authorities

·; Contract for acquisition of 2D and 3D seismic awarded to Acoustic Geophysical Services; survey now in progress

 

Senior management appointment

 

The Company has engaged Frances Morris-Jones in the new position of Business Development Director, with immediate effect. While the Company's primary strategy will continue to be the further de-risking and appraisal of its six Baltic Basin licences, the Business Development Director will have responsibility for screening, assessing and developing opportunities to complement the Company's core activity in the Baltic Basin, with a focus on unconventional oil and gas, as was outlined at the time of the Company's initial public offering in June 2011.

 

Prior to joining 3Legs Resources, Frances Morris-Jones acted as Global Business Development Manager, Unconventional Resources, at ConocoPhillips from 2008 to 2011. In that role, she was involved in negotiating, closing and implementing a number of transactions in Europe and Asia on behalf of ConocoPhillips including the farm-in into 3Legs Resources' Baltic Basin licences in 2009. Prior to joining ConocoPhillips, she spent over 25 years with BP, including latterly as Vice-President, Renewal - Unconventional Gas, where she was responsible for developing the Group's international unconventional gas strategy and led a multi-disciplinary team to screen, rank and assess new opportunities. Frances Morris-Jones is also a non-executive director of Det Norske Veritas, the global provider of services for managing risk, including to the energy and oil & gas sectors.

 

Southern Poland concessions

 

The Company has agreed changes to the terms of its three licences in Southern Poland with the Polish Ministry of Environment and licence amendments have been issued. These changes enable the Company to acquire approximately 70 km of 2D and approximately 50 sq km of 3D seismic data, to be followed by the drilling of an exploration well. The Company has awarded a contract for the seismic acquisition to Acoustic Geophysical Services and the survey is now well advanced. The Company then expects to drill one well on these licences in 2012.

 

Peter Clutterbuck, Chief Executive of 3Legs Resources, said:

 

"We are very pleased to welcome on board Frances Morris-Jones as Business Development Director.  She brings with her a wealth of experience in unconventional oil and gas from her time spent with ConocoPhillips and with BP. She will be a valuable addition to the management team and will have an important role in the formulation and implementation of our strategy going forward, including in relation to our core asset in the Baltic Basin. Our primary focus remains the commercial development of the Baltic Basin where we are continuing to do further analysis on the results of our two recent wells and we are engaged in a planning process for the 2012 programme."

 

 

For further information contact:

 

3Legs Resources plc

Tel:

+44 1624 811 611

Peter Clutterbuck, Chief Executive Officer

Alexander Fraser, Chief Financial Officer

Jefferies International Limited

Tel:

+44 207 029 8000

Chris Snoxall

Alex Grant

College Hill

Tel:

+44 207 457 2020

Nick Elwes

Catherine Maitland

 

 

Notes to Editors

 

3Legs Resources was established in early 2007 to focus on the exploration and development of unconventional oil and gas resources, with a particular focus on shale gas in Europe. A first mover in Poland, 3Legs Resources has acquired six licences covering approximately 1,084,000 acres (gross) in the onshore Baltic Basin, a region considered to be one of the most promising shale basins in Europe. The Company's primary targets in the Baltic Basin are the organic-rich black shales of the Lower Palaeozoic section. In addition to these assets, the Company holds onshore exploration licences over acreage near Krakow in southern Poland and in Baden-Württemberg in south-west Germany.

 

The technical information and opinions contained in this announcement have been reviewed by Peter Clutterbuck (MA Honours in Engineering, Cambridge University and former Member of the Board of the Society of Petroleum Engineers in London), Chief Executive Officer of 3Legs Resources plc, who has over 35 years of experience in the oil exploration and production industry. He has consented to the inclusion herein of such technical information and opinions.

 

www.3legsresources.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQKLBLFFFZFBD
Date   Source Headline
9th Jan 20202:30 pmRNSCancellation of trading on AIM
20th Dec 201910:30 amRNSCancellation of AIM listing /Potential acquisition
27th Sep 201911:07 amRNSHalf-year Report - Correction
26th Sep 20192:06 pmRNSHalf-year Report
23rd Sep 20193:02 pmRNSAIM Rule 17 Notification
9th Jul 20197:30 amRNSSuspension - SalvaRx Group Plc
9th Jul 20197:30 amRNSSuspension of Trading
28th Jun 201911:26 amRNSFinal Results
31st Jan 20197:00 amRNSChange of Nominated Adviser and Broker
17th Jan 20192:05 pmRNSSecond Price Monitoring Extn
17th Jan 20192:00 pmRNSPrice Monitoring Extension
8th Jan 20194:15 pmRNSResult of AGM and Completion of Disposal
4th Jan 20195:30 pmRNSSalvarx Group
14th Dec 20187:50 amRNSNominated Adviser Status
10th Dec 20187:00 amRNSIssue of US$1 million of Loan Notes by iOx
27th Nov 20187:00 amRNSPosting of Circular and Notice of AGM
21st Nov 20181:00 pmRNSTransaction Update
6th Nov 20187:00 amRNSDirector/PDMR Dealing
22nd Oct 20189:47 amRNSIntensity Therapeutics Update
9th Oct 20187:00 amRNSExercise of Warrants
27th Sep 20187:00 amRNSHalf-year Report
28th Aug 20185:40 pmRNSUpdate re proposed disposal and demerger
14th Aug 20187:00 amRNSProposed disposal of interest in SalvaRx Limited
1st Aug 20184:40 pmRNSSecond Price Monitoring Extn
1st Aug 20184:35 pmRNSPrice Monitoring Extension
23rd Jul 20181:17 pmRNSDelay in iOx development programme
28th Jun 20187:00 amRNSFinal Results
26th Jun 20187:00 amRNSRelated Party Loan of US$1 million
8th Mar 201812:00 pmRNSDrug Pipeline Progress and iOx Loan Note Issue
30th Oct 20174:40 pmRNSSecond Price Monitoring Extn
30th Oct 20174:35 pmRNSPrice Monitoring Extension
23rd Oct 20177:00 amRNSSubscriptions for SalvaRx Ltd Loan Facility
27th Sep 20179:00 amRNSHalf-year Report
25th Sep 20178:00 amRNSFormation of Saugatuck Therapeutics
1st Aug 20173:30 pmRNSHolding(s) in Company
1st Aug 20173:30 pmRNSHolding(s) in Company
31st Jul 20171:45 pmRNSResult of AGM
5th Jul 20173:03 pmRNSNotice of AGM
30th Jun 20178:34 amRNSFinal Results
30th May 201712:45 pmRNSIntensity Therapeutics Treats First Patient
20th Mar 20177:00 amRNSInvestment in Rift Biotherapeutics
2nd Mar 20177:00 amRNSRestructuring, Loan Conversion and Loan Facility
28th Feb 20177:00 amRNSInvestment in Nekonal
2nd Feb 20174:37 pmRNSIntensity Therapeutics
3rd Oct 20164:40 pmRNSSecond Price Monitoring Extn
3rd Oct 20164:35 pmRNSPrice Monitoring Extension
14th Sep 20167:00 amRNSCorporate Video
13th Sep 20167:00 amRNSHalf-year Report
22nd Aug 20167:00 amRNSDrug Pipeline Progress including Patent Grants
4th Aug 20162:05 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.